ABSTRACT
Introduction Two landmark clinical trials, CONSENSUS I and SOLVD-T, have shown, unequivocally, that angiotensin converting enzyme (ACE) inhibitors reduce all cause mortality in patients with chronic heart failure (CHF) and underlying left ventricular (LV) systolic dysfunction.1,2 These and other trials have also confirmed that ACE inhibitors reduce morbidity, as manifest by hospital admission, in patients with CHF.3
